We restore endothelial cell function

About Pantherna

Pantherna Therapeutics is a privately-held biopharmaceutical company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium.

Our Science

Latest News

PRESS RELEASE
02 April, 2020
Successful follow-up financing for Pantherna Therapeutics’ development programs to fight Acute Respiratory Distress Syndrome
  • The life science startup Pantherna Therapeutics secures capital in the amount of EUR 3.0 million in successful follow-up financing.
  • Pantherna has a proprietary, innovative mRNA technology platform for the development of new types of therapeutics to treat acute respiratory distress syndrome, a lung disease that is caused among others by the Coronavirus.
  • The funds raised will accelerate Pantherna’s R&D activities and broaden them.
  • Renowned European Business Angel Prof. Detlev Riesner together with the European Investment Fonds and a private investor contribute to this round.
Full text (ENG)
Full text (DE)
All News

Our Team

(from left to right)
Dr. Daniel Tondera
Head of Biology
Dr. Gerrit Maass
CFO
Dr. Jörg Kaufmann
CSO
Dr. Volker Fehring
Head of Formulation
Dr. Oliver Keil
CTO
Dr. Klaus Giese
CEO

Our Locations

Headquarters

Pantherna Therapeutics GmbH
Innovationsforum Hennigsdorf

Neuendorfstrasse 20b
D-16761 Hennigsdorf
Germany

R&D Site

Pantherna Therapeutics GmbH
Bayer AG CoLaborator Berlin

Müllerstraße 178
D-13353 Berlin
Germany

How can we help?

Please note our Privacy Policy

Public Funding

Pantherna is supported by public funding from the EU (EFRE). EFRE is provided by the State Brandenburg  through the following programs “ProFIT and Gründung Innovativ:

#80174940 „Förderung von Forschung, Innovationen und Technologien ProFIT (ab 2014) ProFIT: Zelltyp-spezifische Expression therapeutischer Proteine (AP 1, 2, 3, 4)“

#80174941 „Förderung von Forschung, Innovationen und Technologien ProFIT (ab 2014) ProFIT: Zelltyp-spezifische Expression therapeutischer Proteine (AP 5 und 6)“

#85026035 „Gründung Innovativ 2015 – 2020 Optimierung der Herstellung von mRNA-Konstrukten für die in-vivo Expression von therapeutischen Proteinen i. d. Vaskulation“